全文获取类型
收费全文 | 177497篇 |
免费 | 33145篇 |
国内免费 | 2427篇 |
专业分类
耳鼻咽喉 | 5431篇 |
儿科学 | 6261篇 |
妇产科学 | 3066篇 |
基础医学 | 6589篇 |
口腔科学 | 1952篇 |
临床医学 | 29762篇 |
内科学 | 52263篇 |
皮肤病学 | 7734篇 |
神经病学 | 17087篇 |
特种医学 | 7305篇 |
外国民族医学 | 1篇 |
外科学 | 44178篇 |
综合类 | 902篇 |
现状与发展 | 72篇 |
一般理论 | 21篇 |
预防医学 | 10033篇 |
眼科学 | 4270篇 |
药学 | 2861篇 |
中国医学 | 28篇 |
肿瘤学 | 13253篇 |
出版年
2024年 | 701篇 |
2023年 | 4910篇 |
2022年 | 1421篇 |
2021年 | 3605篇 |
2020年 | 6304篇 |
2019年 | 2701篇 |
2018年 | 7974篇 |
2017年 | 7775篇 |
2016年 | 8860篇 |
2015年 | 8940篇 |
2014年 | 16193篇 |
2013年 | 16643篇 |
2012年 | 7020篇 |
2011年 | 7053篇 |
2010年 | 11121篇 |
2009年 | 14972篇 |
2008年 | 7121篇 |
2007年 | 5402篇 |
2006年 | 7793篇 |
2005年 | 5005篇 |
2004年 | 4207篇 |
2003年 | 3161篇 |
2002年 | 3173篇 |
2001年 | 4397篇 |
2000年 | 3640篇 |
1999年 | 3776篇 |
1998年 | 3916篇 |
1997年 | 3701篇 |
1996年 | 3582篇 |
1995年 | 3452篇 |
1994年 | 2171篇 |
1993年 | 1779篇 |
1992年 | 1824篇 |
1991年 | 1877篇 |
1990年 | 1480篇 |
1989年 | 1608篇 |
1988年 | 1381篇 |
1987年 | 1210篇 |
1986年 | 1250篇 |
1985年 | 1056篇 |
1984年 | 818篇 |
1983年 | 740篇 |
1982年 | 695篇 |
1981年 | 560篇 |
1980年 | 516篇 |
1979年 | 520篇 |
1978年 | 502篇 |
1977年 | 559篇 |
1975年 | 411篇 |
1972年 | 444篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
Adrenal disorders in pregnancy. 总被引:1,自引:0,他引:1
76.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
77.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
78.
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. 总被引:2,自引:0,他引:2
Mitchell L Shiffman Moisés Diago Albert Tran Paul Pockros Robert Reindollar Daniele Prati Maribel Rodríguez-Torres Pilar Lardelli Steven Blotner Stefan Zeuzem 《Clinical gastroenterology and hepatology》2006,4(5):645-652
BACKGROUND & AIMS: Many patients with chronic hepatitis C virus (HCV) have persistently normal serum alanine transaminase (ALT) levels. We compared characteristics of chronic hepatitis C patients with patients with normal and elevated ALT levels using data from 3 randomized phase III trials of peginterferon alfa-2a (40 kDa). METHODS: The characteristics of 480 patients with normal ALT values (on >or=3 occasions without any increases in ALT level over a 6- to 18-month period) and 1993 patients with elevated ALT levels were compared. Sixty-eight of the 480 patients with normal ALT levels were randomized to no treatment and monitored for 72 weeks. RESULTS: More patients with normal ALT levels than patients with elevated ALT levels were women (59% vs 32%; P<.01). The serum HCV RNA titer was significantly lower in patients with normal ALT levels (P<.01 vs in patients with elevated ALT levels). Patients with normal ALT levels had significantly lower inflammation and fibrosis scores on liver biopsy examination than patients with elevated ALT levels, but almost two-thirds had portal fibrosis and 10% had bridging fibrosis. No correlation between baseline ALT activity, HCV RNA level, and liver histology was observed in patients with normal ALT levels. During the 72-week follow-up period, ALT activity elevated above the upper limit of normal in 53% of the untreated patients with normal levels of ALT. None became HCV RNA undetectable. CONCLUSIONS: Chronic hepatitis C patients with normal ALT levels should be evaluated in a similar manner as patients with elevated ALT levels because they are at risk for developing significant liver disease. The decision to treat with peginterferon alfa and ribavirin should be based on multiple factors, rather than on ALT levels alone. 相似文献
79.
80.
INTRODUCTION: The clinical presentation of morphea varies from localized plaques to generalized eruptions. Its cause remains unknown and medical treatments have often proved unsatisfactory. Studies have previously shown that improvement of hypertrophic scars and fibrotic skin can be achieved with the use of a 585 nm pulsed dye laser (PDL). METHODS: A case of plaque-type morphea was treated with 585 nm pulsed dye laser irradiation at an average fluence of 5.0 J/cm2 at bimonthly time intervals. RESULTS: Marked clinical improvement as evidenced by improved pliability and skin coloration was seen after 4 successive PDL treatments. No side effects or complications were encountered. CONCLUSION: Pulsed dye laser therapy is a viable treatment option for morphea. The mechanism of its effect in this condition remains unknown. 相似文献